Taken from the last Ann
All participants completing the Treatment Period of the study will be offered to the enter an open label extension
study of ATL1102 conducted under a separate protocol and will be given the highest dose tested in the study or
the highest dose considered generally safe and well tolerated in the study. This will serve to further increase the
safety and efficacy database.
- Forums
- Charts
- Chart
Taken from the last Ann All participants completing the...
-
- There are more pages in this discussion • 4,637 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.6¢ |
Change
-0.001(1.30%) |
Mkt cap ! $68.51M |
Open | High | Low | Value | Volume |
7.9¢ | 7.9¢ | 7.6¢ | $15.61K | 200K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 138642 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 0.077 |
1 | 49195 | 0.076 |
2 | 113467 | 0.075 |
1 | 200000 | 0.072 |
1 | 20000 | 0.071 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 138642 | 4 |
0.081 | 120000 | 1 |
0.083 | 206000 | 2 |
0.085 | 250000 | 2 |
0.087 | 25001 | 1 |
Last trade - 12.51pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
7.9¢ |
  |
Change
-0.001 ( 1.28 %) |
|||
Open | High | Low | Volume | ||
7.9¢ | 7.9¢ | 7.9¢ | 6979 | ||
Last updated 12.03pm 06/05/2024 ? |
Featured News
PER (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online